Group 1 - The core viewpoint of the article highlights Daqing Huake's stock performance, with a closing price of 16.2 yuan, an increase of 3.05%, and a rolling PE ratio of 42.04 times, with a total market value of 2.1 billion yuan [1] - The company operates in the petrochemical industry, producing and selling various products including C9 and C5 series petroleum resins, refined acetonitrile, polypropylene powder, and modified polyolefin plastics [1] - Daqing Huake has achieved significant technological advancements, holding 13 national patents, including 8 invention patents, all of which have been industrialized, indicating a leading position in domestic technology [1] Group 2 - The latest financial results for the third quarter of 2024 show that the company achieved an operating income of 1.505 billion yuan, a year-on-year increase of 4.41%, and a net profit of 31.1297 million yuan, a year-on-year increase of 336.63%, with a gross profit margin of 7.73% [1] - In terms of market performance, Daqing Huake ranks 112th in the chemical products industry, which has an average PE ratio of 50.85 times and a median of 36.13 times [2] - The net inflow of main funds for Daqing Huake on April 14 was 139,500 yuan, although there was an overall outflow of 5.9542 million yuan over the past five days [1]

Core Viewpoint - Daqing Huake's stock price increased by 3.27% to 15.79 yuan, with a rolling PE ratio of 40.97 times, and a total market value of 2.047 billion yuan [1] Company Overview - Daqing Huake specializes in the production and sales of petrochemical products, including C9 and C5 series petroleum resins, refined acetonitrile, polypropylene powder, and modified polyolefin plastics [1] - The company holds 13 national patents, including 8 invention patents, all of which have been industrialized, with its product technology at a leading domestic level [1] Financial Performance - For the third quarter of 2024, Daqing Huake reported operating revenue of 1.505 billion yuan, a year-on-year increase of 4.41%, and a net profit of 31.1297 million yuan, a year-on-year increase of 336.63%, with a gross profit margin of 7.73% [1] Shareholder Information - As of September 30, 2024, Daqing Huake had 9,251 shareholders, an increase of 170 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the chemical products industry is 47.84 times, with a median of 35.68 times, placing Daqing Huake at the 112th position in the industry [2]

Company Overview - Daqing Huake's closing price on April 1 was 17.18 yuan, with an increase of 1.24%, resulting in a rolling PE ratio of 44.58 times and a total market value of 2.227 billion yuan [1] - The company operates in the petrochemical industry, focusing on the production and sales of petrochemical products, import and export business, and warehousing services [1] - Daqing Huake's main products include C9 and C5 series petroleum resins, refined acetonitrile, polypropylene powder, and modified polyolefin plastics [1] Industry Comparison - The average PE ratio for the chemical products industry is 45.97 times, with a median of 35.68 times, placing Daqing Huake at the 116th position in the industry ranking [1][2] - The company has a total of 28 institutional investors holding shares, with a combined holding of 478,300 shares valued at 0.09 billion yuan [1] Financial Performance - For the third quarter of 2024, Daqing Huake reported an operating income of 1.505 billion yuan, representing a year-on-year increase of 4.41% [1] - The net profit for the same period was 31.1297 million yuan, showing a significant year-on-year increase of 336.63%, with a sales gross margin of 7.73% [1] - The company holds 13 national patents, including 8 invention patents, all of which have been industrialized, with its core technologies being proprietary and leading in the domestic market [1]

证券代码：000985 证券简称：大庆华科 公告编号：2025002 大庆华科股份有限公司 关于审计机构变更签字注册会计师 和质量控制复核人的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 大庆华科股份有限公司（以下简称"公司"）分别于 2024 年 10 月 25 日、2024 年 11 月 15 日召开第九届董事会 2024 年第一次临时 会议、2024 年第一次临时股东大会，审议通过了《关于拟续聘公司 2024 年度审计机构的议案》，同意续聘天健会计师事务所（特殊普通 合伙）（以下简称"天健会计师事务所"）为公司 2024 年度财务审计 和内部控制审计机构。具体内容详见公司于 2024 年 10 月 26 日、2025 年 11 月 16 在《中国证券报》《上海证券报》及巨潮资讯网上披露的 《关于拟续聘 2024 年度审计机构的公告》（公告编号：2024028）及 《2024 年第一次临时股东大会决议公告》（公告编号：2024032）。 近日，公司收到天健会计师事务所出具的《关于变更签字注册会 计师和质量控制复核人员的函》，现将相关情况公告如下： 一 ...

编号：2025001 问题四、公司在 C5、C9 等传统主营业务外，近两年是否具 备新的利润增长点？ 答：1、2024 年，公司 1.08 万吨/年丁二烯抽提装置碳四炔 烃尾气回收装置于 4 月份开工建设，10 月开始试生产。该装置 达产后可生产丁烷 1.05 万吨/年，预计年增利润 1200 万元，在 提高企业创效能力的同时对区域环保具有积极意义。 | 投资者关系活动 | 分析师会议 □特定对象调研 □ | | --- | --- | | 类别 □ | 媒体采访 □业绩说明会 | | □ | 新闻发布会 □ 路演活动 | | □ | 现场参观 | | √ | 其他 （视频会议） | | 参与单位名称及 | 北京世邦私募基金管理有限公司：崔卫国、于千可、杨力 | | 人员姓名 | | | 时间 | 年 月 日 2025 1 22 (周三) 14；00~15:00 | | 地点 | 视频会议 | | 上市公司接待人 | 董事会秘书孟凡礼 | | 员姓名 | 证券事务代表崔凤玲 | | | 问题一、请问公司上游原料的基本情况及主营产品对应的客 | | | 户是哪些行业的？ | | | 答：公司主要以中国石油天然气 ...

Financial Performance - The net profit attributable to shareholders is expected to be between 13 million and 16 million yuan, representing a year-on-year increase of 129.01% to 181.85%[3] - The net profit after deducting non-recurring gains and losses is also projected to be between 13 million and 16 million yuan, with a year-on-year growth of 1150.36% to 1438.91%[3] - The basic earnings per share is estimated to be between 0.100 yuan and 0.123 yuan, compared to 0.044 yuan per share in the previous year[3] Operational Efficiency - The company has improved production organization and efficiency, leading to significant increases in raw material processing, product output, operating income, and net profit[5] - The company conducted routine maintenance from June to August 2023, resulting in stable operations of major production facilities[5] Financial Data and Reporting - The financial data in the performance forecast has not been audited by registered accountants, and final figures may differ from the preliminary estimates[4] - The company has communicated with the accounting firm regarding the performance forecast, with no significant disagreements reported[4] Caution and Risk Awareness - The company emphasizes the importance of cautious decision-making and awareness of investment risks due to potential discrepancies in financial data[7] Disclosure Information - The official disclosure media for the company’s information includes "China Securities Journal," "Shanghai Securities Journal," and the Giant Tide Information Network[7] Performance Forecast Period - The performance forecast period is from January 1, 2024, to December 31, 2024[2]

任信有限公司 哈 产 PAN-CHINA ASSETS VALUATION CO.,LTD. 本报告依据中国资产评估准则编制 大庆华科股份有限公司拟处置资产 涉及的药业分公司相关资产市场价值 资产评估报告 众华评报字[2024]第 055 号 共一册,第一册 辽宁众华资产评估有限公司 二〇二四年十一月十一日 and and the submit and 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 2424020043202400061 | | | | --- | --- | --- | --- | | 合同编号: | 委评20230302-1 | | | | 报告类型: | 非法定评估业务资产评估报告 | | | | 报告文号: | 众华评报字[2024]第055号 | | | | 报告名称: | 大庆华科股份有限公司拟处置资产涉及的药业分公 司相关资产市场价值 | | | | 评估结论: | 54,461,610.00元 | | | | 评估报告日: | 2024年11月11日 | | | | 评估机构名称: | 辽宁众华资产评估有限公司 | | | | 签名人员: | 孙晓莉 | (资 ...

任信有限公司 哈 产 PAN-CHINA ASSETS VALUATION CO.,LTD. 大庆华科股份有限公司拟处置资产 涉及的药业分公司相关资产市场价值 资产评估说明 众华评报字[2024]第 055 号 共一册,第一册 辽宁众华资产评估有限公司 二〇二四年十一月十一日 and and the first of the many of the comments of the 大庆华科股份有限公司拟处置资产涉及的药业分公司相关资产市场价值 资产评估说明 资产评估说明目录 | 第一部分 关于《资产评估说明》使用范围的声明 . | | --- | | 第二部分 企业关于进行资产评估有关事项的说明 . | | 第三部分 资产评估说明正文 | | 一、 评估对象与评估范围说明 . | | (一)评估对象与评估范围内容 - | | (二)实物资产分布情况及特点 | | (三)企业申报的账面记录或者未记录的无形资产情况 . | | (四)企业申报的表外资产的类型、数量 . | | (五)引用其他机构出具的结论 . | | 二、资产核实情况总体说明 | | (一)资产核实人员组织、实施时间和过程说明 | | (二)影响 ...

证券代码：000985 证券简称：大庆华科 公告编号：2024034 大庆华科股份有限公司 3.本次通过公开挂牌方式的拟转让资产，挂牌受让方和最终交易 价格目前尚未确定，尚无法判断是否构成关联交易。 4.本次交易已经公司第九届董事会 2024 年第二次临时会议通过， 并已经履行评估结果备案程序，已经取得主管部门的批准，无需提交 公司股东大会审议。 关于转让药业分公司部分资产的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、交易内容： （1）公司拟在产权交易所通过公开挂牌方式转让药业分公司机 器设备资产，转让价格不低于资产评估机构对标的资产的评估价值， 最终交易对手和交易价格将根据国有产权交易规则市场化产生和确 定。 （2）公司拟以评估价值为基础，对药业分公司外围道路及绿化 用地按货币化补偿方式交由政府进行有偿收储。 2.本次交易不构成《上市公司重大资产重组管理办法》规定的重 大资产重组。交易实施不存在重大法律障碍。 5.本次交易结果存在不确定性，公司将根据本次交易的工作进度， 及时披露交易进展公告，履行信息披露义务。敬请广大投资者注意投 ...

大庆华科股份有限公司拟处置资产 涉及的药业分公司相关资产市场价值 资产评估报告 本报告依据中国资产评估准则编制 众华评报字[2024]第 053 号 共一册,第一册 辽宁众华资产评估有限公司 任信有限公司 哈 产 PAN-CHINA ASSETS VALUATION CO.,LTD. 备案回执生成日期:2024年11月11日 大庆华科股份有限公司拟处置资产涉及的药业分公司相关资产市场价值 资产评估报告 资产评估报告目录 二〇二四年十一月十一日 ] 】【，】 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 2424020043202400060 | | | --- | --- | --- | | 合同编号: | 委评20230302 | | | 报告类型: | 非法定评估业务资产平任报告 | | | 报告文号: | 众华评报字 2024 第053号 | | | 报告名称: | 十年任科盟份有限公司拟处置给产次次的约业才公 司相关资产市场价值 | | | 评估结论: | 3.833.800.00元 | | | 评估报告日: | 2024年11月11日 | | | 评估机构名称: | 订宁众华资产评 ...